logo-loader

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Published: 12:51 19 Apr 2018 BST

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system.

Not only have they discovered a method of successfully culturing the cancer cells from blood samples taken using Parsortix, they have also designed a work flow for the process.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24